Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Pharmaceuticals

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 12:45:00 01/07/2024 pm IST 		5-day change 1st Jan Change
3.4 ILa 0.00% Intraday chart for Can-Fite BioPharma Ltd. -2.86% +30.77%
28/06 Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix CI
24/06 Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 12.97 28.72 38.62 19.52 8.817 13.52 - -
Enterprise Value (EV) 1 12.97 28.72 19.48 19.52 8.817 13.52 13.52 13.52
P/E ratio -0.95 x -1.49 x -1.52 x -2.35 x -0.71 x - - -
Yield - - - - - - - -
Capitalization / Revenue 6.38 x 37.6 x 45.3 x 24.1 x 11.9 x 15 x 15 x 16.9 x
EV / Revenue 6.38 x 37.6 x 45.3 x 24.1 x 11.9 x 15 x 15 x 16.9 x
EV / EBITDA - - - - - - - -
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 1,19,656 4,63,769 8,15,746 8,15,746 12,24,837 14,97,128 - -
Reference price 2 0.3740 0.1990 0.1470 0.0840 0.0260 0.0340 0.0340 0.0340
Announcement Date 27/03/20 25/03/21 24/03/22 30/03/23 28/03/24 - - -
1ILS in Million2ILS
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2.032 0.763 0.853 0.81 0.743 0.9 0.9 0.8
EBITDA - - - - - - - -
EBIT 1 -12 -14.14 -12.84 -10.1 -8.195 -8.175 -9.2 -8.725
Operating Margin -590.7% -1,853.08% -1,505.51% -1,246.42% -1,102.96% -908.33% -1,022.22% -1,090.62%
Earnings before Tax (EBT) 1 -9.587 -14.44 -12.62 -10.17 -7.634 -9.1 -10.6 -
Net income 1 -9.587 -14.44 -12.62 -10.17 -7.634 -7.875 -8.9 -8.325
Net margin -471.8% -1,892.92% -1,478.9% -1,255.93% -1,027.46% -875% -988.89% -1,040.62%
EPS 2 -0.3942 -0.1332 -0.0967 -0.0358 -0.0367 - - -
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 27/03/20 25/03/21 24/03/22 30/03/23 28/03/24 - - -
1USD in Million2ILS
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 0.251 0.204 0.205 0.204 0.204 0.197 0.196 0.196 0.196 0.155 0.3 0.3 0.3 0.3
EBITDA - - - - - - - - - - - - - -
EBIT 1 -3.51 -4.028 -2.37 -2.07 -2.573 -3.083 - -1.784 -1.865 -1.834 -1.9 -2.1 -2.4 -2.8
Operating Margin -1,398.41% -1,974.51% -1,156.1% -1,014.71% -1,261.27% -1,564.97% - -910.2% -951.53% -1,183.23% -633.33% -700% -800% -933.33%
Earnings before Tax (EBT) 1 -3.4 -4.118 -2.434 -2.191 -2.529 -3.019 - -1.67 -1.762 -1.652 -1.9 -2.1 -2.4 -2.7
Net income 1 -3.4 -4.118 -2.434 -2.191 -2.529 -3.019 - -1.67 -1.762 -1.652 -1.9 -2.1 -2.4 -2.7
Net margin -1,354.58% -2,018.63% -1,187.32% -1,074.02% -1,239.71% -1,532.49% - -852.04% -898.98% -1,065.81% -633.33% -700% -800% -900%
EPS 2 -0.0319 -0.0322 - - -0.0342 - - - - -0.0367 - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 26/11/21 24/03/22 26/05/22 25/08/22 25/11/22 30/03/23 01/06/23 31/08/23 30/11/23 28/03/24 - - - -
1USD in Million2ILS
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - 19.1 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - 0.01 - - - - -
Capex / Sales - - 1.29% - - - - -
Announcement Date 27/03/20 25/03/21 24/03/22 30/03/23 28/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Can-Fite BioPharma Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.034
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CAN-FITE BIOPHARMA LTD. Stock Can-Fite BioPharma Ltd.
+30.77% 13.52M
CSL LIMITED Stock CSL Limited
+2.08% 95.18B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-4.34% 37.55B
UCB Stock UCB
+74.97% 28.2B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.61% 15.63B
INCYTE CORPORATION Stock Incyte Corporation
-3.46% 13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.31% 11.5B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+184.77% 10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.13% 9.23B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.62% 9.09B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CANF Stock
  4. Financials Can-Fite BioPharma Ltd.